论文部分内容阅读
目的探讨NAD(P)H氧化酶P22phox亚基C242T基因多态性与以蒽环类药物为基础的化疗方案治疗弥漫大B细胞淋巴瘤化疗疗效的关系。方法收集经病理形态学和免疫组织化学确诊DLBCL患者32例,采用PCR-RFLP技术检测C242T位点的基因型,观察其不同基因型与化疗效果的关系。结果 32例DLBCL患者中,CC基因型22例(68.8%),CT基因型10例(31.2%),其中16例完全缓解,9例部分缓解,近期缓解率为78.1%。其中CC型有效20例(62.5%),CT型有效5例(15.6%),差异有统计学意义(P=0.019)。结论野生基因型(CC)对以蒽环类为基础化疗敏感,临床疗效优于突变型。
Objective To investigate the relationship between the C242T gene polymorphism of P22phox subunit of NAD (P) H oxidase and the chemotherapy effect of anthracycline-based chemotherapy in the treatment of diffuse large B cell lymphoma. Methods Totally 32 cases of DLBCL confirmed by pathomorphology and immunohistochemistry were collected. The genotypes of C242T locus were detected by PCR-RFLP and the relationship between different genotypes and chemotherapeutic effect was observed. Results Among the 32 patients with DLBCL, CC genotype was 22 (68.8%) and CT genotype was 10 (31.2%), of which 16 were completely relieved and 9 were partly relieved. The recent remission rate was 78.1%. Among them, CC type was effective in 20 cases (62.5%) and CT type was effective in 5 cases (15.6%), the difference was statistically significant (P = 0.019). Conclusions Wild type genotype (CC) is sensitive to anthracycline-based chemotherapy and has better clinical efficacy than mutant type.